Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Recruiting · NCT05100069 · Observational (researchers observe without assigning treatment) · Lead sponsor: Takeda
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.
Exclusion criteria
- Participants who has a history of hypersensitivity to any component of birigatinib.
Where it is running
1 location listed.
- Takeda Selected Site - Tokyo, Japan